Direct-acting antiviral treatment in real world patients with hepatitis C not associated with psychiatric side effects: a prospective observational study
Abstract Background Treatment of Hepatitis C virus (HCV) infection has evolved from interferon (IFN)-based treatments to direct-acting antivirals (DAAs). Patients with HCV have an elevated psychiatric morbidity (including substance abuse) and patients with such comorbidity have often been excluded f...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2018-05-01
|
Series: | BMC Psychiatry |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12888-018-1735-6 |
id |
doaj-d6bebe6020254c7dad6aa25a43e16638 |
---|---|
record_format |
Article |
spelling |
doaj-d6bebe6020254c7dad6aa25a43e166382020-11-25T02:20:17ZengBMCBMC Psychiatry1471-244X2018-05-011811910.1186/s12888-018-1735-6Direct-acting antiviral treatment in real world patients with hepatitis C not associated with psychiatric side effects: a prospective observational studyIsak Sundberg0Anders Lannergård1Mia Ramklint2Janet L. Cunningham3Department of Neuroscience, Psychiatry, Uppsala University HospitalDepartment of Medical Sciences, Section of Infectious Diseases, Uppsala University HospitalDepartment of Neuroscience, Psychiatry, Uppsala University HospitalDepartment of Neuroscience, Psychiatry, Uppsala University HospitalAbstract Background Treatment of Hepatitis C virus (HCV) infection has evolved from interferon (IFN)-based treatments to direct-acting antivirals (DAAs). Patients with HCV have an elevated psychiatric morbidity (including substance abuse) and patients with such comorbidity have often been excluded from treatment with IFN. To date, little is known about psychiatric adverse effects of DAA-based regimens. We therefore aimed to study the psychiatric side effects of new IFN-free treatment for HCV (including depressive symptoms and sleep) in real world patients also including those with a history of psychiatric diagnosis, substance abuse or drug dependence. Methods Consecutive patients were monitored during treatment with three of the latest DAA agents (sofosbuvir, simeprevir and daclatasvir). Repeated expert psychiatric assessments from baseline to 12 weeks post-treatment were performed with the Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I) clinical version and the self-report versions of the Montgomery Åsberg Depression Rating Scale (MADRS-S) and the Pittsburgh Sleep Quality Index (PSQI). Friedman’s test was performed to calculate differences in the MADRS-S and PSQI over time. In a post-hoc analysis Wilcoxon’s test was used to compare baseline depressive symptoms with those at post-treatment. Spearman’s rank correlation test was conducted in another post-hoc analysis to evaluate the correlation between symptoms of depression and HCV viral load at baseline. Results At baseline, 15/17 patients (88%) had a history of any psychiatric diagnosis; 11 (65%) had a history of substance abuse or dependence; and 11 (65%) had previously been treated with IFN and six of those had experienced psychiatric side effects. There was no correlation between depressive symptoms and HCV viral load at baseline. Symptoms of depression did not increase during DAA treatment and were lower 12 weeks post-treatment compared with baseline: MADRS-S 10.7 vs. 8.3 (p = 0.01). This observation held when excluding patients taking antidepressant medication. Sleep quality did not significantly change during treatment. Adherence to treatment was estimated to 95% and sustained virological response was 88%. Conclusions Despite high psychiatric morbidity, including previous substance abuse, patients successfully completed DAA treatment without increasing depressive symptoms or sleep disturbance. Symptoms of depression were significantly reduced 12 weeks after DAA treatment.http://link.springer.com/article/10.1186/s12888-018-1735-6Hepatitis C virusDirect-acting antiviralDepressionSleepSide effects |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Isak Sundberg Anders Lannergård Mia Ramklint Janet L. Cunningham |
spellingShingle |
Isak Sundberg Anders Lannergård Mia Ramklint Janet L. Cunningham Direct-acting antiviral treatment in real world patients with hepatitis C not associated with psychiatric side effects: a prospective observational study BMC Psychiatry Hepatitis C virus Direct-acting antiviral Depression Sleep Side effects |
author_facet |
Isak Sundberg Anders Lannergård Mia Ramklint Janet L. Cunningham |
author_sort |
Isak Sundberg |
title |
Direct-acting antiviral treatment in real world patients with hepatitis C not associated with psychiatric side effects: a prospective observational study |
title_short |
Direct-acting antiviral treatment in real world patients with hepatitis C not associated with psychiatric side effects: a prospective observational study |
title_full |
Direct-acting antiviral treatment in real world patients with hepatitis C not associated with psychiatric side effects: a prospective observational study |
title_fullStr |
Direct-acting antiviral treatment in real world patients with hepatitis C not associated with psychiatric side effects: a prospective observational study |
title_full_unstemmed |
Direct-acting antiviral treatment in real world patients with hepatitis C not associated with psychiatric side effects: a prospective observational study |
title_sort |
direct-acting antiviral treatment in real world patients with hepatitis c not associated with psychiatric side effects: a prospective observational study |
publisher |
BMC |
series |
BMC Psychiatry |
issn |
1471-244X |
publishDate |
2018-05-01 |
description |
Abstract Background Treatment of Hepatitis C virus (HCV) infection has evolved from interferon (IFN)-based treatments to direct-acting antivirals (DAAs). Patients with HCV have an elevated psychiatric morbidity (including substance abuse) and patients with such comorbidity have often been excluded from treatment with IFN. To date, little is known about psychiatric adverse effects of DAA-based regimens. We therefore aimed to study the psychiatric side effects of new IFN-free treatment for HCV (including depressive symptoms and sleep) in real world patients also including those with a history of psychiatric diagnosis, substance abuse or drug dependence. Methods Consecutive patients were monitored during treatment with three of the latest DAA agents (sofosbuvir, simeprevir and daclatasvir). Repeated expert psychiatric assessments from baseline to 12 weeks post-treatment were performed with the Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I) clinical version and the self-report versions of the Montgomery Åsberg Depression Rating Scale (MADRS-S) and the Pittsburgh Sleep Quality Index (PSQI). Friedman’s test was performed to calculate differences in the MADRS-S and PSQI over time. In a post-hoc analysis Wilcoxon’s test was used to compare baseline depressive symptoms with those at post-treatment. Spearman’s rank correlation test was conducted in another post-hoc analysis to evaluate the correlation between symptoms of depression and HCV viral load at baseline. Results At baseline, 15/17 patients (88%) had a history of any psychiatric diagnosis; 11 (65%) had a history of substance abuse or dependence; and 11 (65%) had previously been treated with IFN and six of those had experienced psychiatric side effects. There was no correlation between depressive symptoms and HCV viral load at baseline. Symptoms of depression did not increase during DAA treatment and were lower 12 weeks post-treatment compared with baseline: MADRS-S 10.7 vs. 8.3 (p = 0.01). This observation held when excluding patients taking antidepressant medication. Sleep quality did not significantly change during treatment. Adherence to treatment was estimated to 95% and sustained virological response was 88%. Conclusions Despite high psychiatric morbidity, including previous substance abuse, patients successfully completed DAA treatment without increasing depressive symptoms or sleep disturbance. Symptoms of depression were significantly reduced 12 weeks after DAA treatment. |
topic |
Hepatitis C virus Direct-acting antiviral Depression Sleep Side effects |
url |
http://link.springer.com/article/10.1186/s12888-018-1735-6 |
work_keys_str_mv |
AT isaksundberg directactingantiviraltreatmentinrealworldpatientswithhepatitiscnotassociatedwithpsychiatricsideeffectsaprospectiveobservationalstudy AT anderslannergard directactingantiviraltreatmentinrealworldpatientswithhepatitiscnotassociatedwithpsychiatricsideeffectsaprospectiveobservationalstudy AT miaramklint directactingantiviraltreatmentinrealworldpatientswithhepatitiscnotassociatedwithpsychiatricsideeffectsaprospectiveobservationalstudy AT janetlcunningham directactingantiviraltreatmentinrealworldpatientswithhepatitiscnotassociatedwithpsychiatricsideeffectsaprospectiveobservationalstudy |
_version_ |
1724872308125859840 |